Head Cell Therapy Clinical Immunogenicity
Takeda Pharmaceuticals
Cambridge, Massachusetts, United States
Prior to joining Takeda as the Head of Cell Therapy Clinical Immunogenicity, Chris was the Executive Director and Head of Bioanalysis for Syneos Health, overseeing their three bioanalytical laboratories. He was previously the Executive Director for Ligand Binding Services, joining Syneos Health in 2010. Before that, Chris served as Scientific Director of the Ligand Binding/Cell Based Assays at MDS Pharma Services’ North American macromolecule bioanalytical operations where he was responsible for supervising the development and validation of methods for the measurement of pharmaceuticals and biomarkers, immunogenicity testing and Cell Based neutralizing antibody assays.
Before joining MDS Pharma Services in 2004 as a Team Leader in the Ligand Binding Department, Dr. Beaver served as an investigator at Cogent Neuroscience, a startup biotech company in North Carolina’s Research Triangle Park. Dr. Beaver obtained his PhD in Neuroscience at Dalhousie University in Canada in 1995. From 1996 to 2001, he performed his post-doctoral studies at Yale University, focusing on the role of cyclic nucleotides in neuronal development, publishing papers in several journals including Nature Neuroscience.
Disclosure information not submitted.
Tuesday, April 25, 2023
2:30 PM – 3:30 PM ET